Assets

psilocybin (investigator-led; PEX010 capsules, 25 mg and 5 mg)

ARQ Centrum'45

Molecule class

psilocybin

Mechanism

not_applicable

Phase

Phase 2 not yet recruiting

Indication

post-traumatic stress disorder in military veterans

Sponsor geography

NL

Next catalyst

First participant enrolled (start estimated 2026-12), by 2026-12

IP status

not_applicable

The catalyst above is recorded as inferred, not verified. It is this publication's reading of the company's guidance, not a date the company has published.

clinicaltrials.govregistryverified 2026-09-08